Magnetics Business & Technology - March/April 2025 - 15

FEATURE ARTICLE
ship team will be joined by key Greenbrook leadership team
members including Bill Leonard, Greenbrook's current President
and Chief Executive Officer, Peter Willett, Greenbrook's current
Chief Financial Officer, and Dr. Geoffrey Grammer, Greenbrook's
current Chief Medical Officer.
Neuronetics systems are positioned as a non-drug, noninvasive
treatment for people suffering neurohealth problems such as
major depressive disorder (MDD) and anxiety conditions when
traditional medication hasn't helped. The equipment is FDA approved
and covered by many medical insurers.
It is also FDA-cleared as an adjunct for adults with obsessivecompulsive
disorder and for adolescent patients aged 15-21 with
MDD.
From its headquarters in Toronto, Greenbrook operates 130
treatment centers for TMS, also for Spravato (esketamine nasal
spray), both FDA-cleared, non-invasive therapies for the treatment
of MDD and other mental health disorders, in the United
States. Spravato is administered to adults with treatment-resistant
depression and depressive symptoms in adults with MDD
with suicidal thoughts or actions. Greenbrook has provided more
than one million treatments to over 30,000 patients struggling
with depression.
TMS therapy provides local electromagnetic stimulation to
specific brain regions known to be directly associated with mood
regulation. Recently, Health Canada approved TMS after it
showed strong results from some 1,500 clinics in the U.S., likely
creating a significant growth opportunity for the combined enterprise
in Greenbrook's native country.
MDD is a serious mental health condition that causes a persistent
low mood, loss of interest in activities, and other symptoms
that interfere with daily life. Neurostar systems from Neuronetics
have delivered more than 6.4 million treatments for MDD in
adults. There are specific areas in your brain that control mood,
the company explains. When synapses in those mood-regulating
areas are underactive, connections are broken and depression
can result. NeuroStar is designed to revitalize those dormant
synapses, " waking up " the brain to function as it was meant to.
TouchStar Theta Burst
with Contact Sensing from
Neuronetics can dramatically
reduce patient treatment
times. The protocol
involves higher-frequency
pulses than its standard
protocols, shortening sessions
to around 3 minutes.
Traditionally, TMS treatments
can range from 18
to 45 minutes per session.
At the heart of the Neurostar
system is the company's " figure-8 "
coil designed to focus treatment
precisely at the source of the
depression along with its contact
sensing technology to ensure the
prescribed dosage, every treatment,
every pulse.
For more info, see www.neuronetics.
com, www.greenbrooktms.com.
Audemars is a trusted supplier
to world leading medical device
manufacturers. We specialize in
miniature custom components for
active implantable, interventional
and wearable medical devices
and other critical applications. Our
proprietary, low-stress processes
for machining permanent magnet
materials (NdFeB and SmCo) deliver
maximum magnetic performance
in the smallest dimensions
possible. Micro-coil capabilities
include winding ultra-fine wire as
thin as 10 micron. Contact us for
your custom needs.
Small things... make a BIG difference
sales@audemars.com
www.MagneticsMag.com
www.audemars.com
March/April 2025 * Magnetics Business & Technology 15
http://www.neuronetics.com http://www.greenbrooktms.com http://www.neuronetics.com http://www.audemars.com http://www.MagneticsMag.com
Magnetics Business & Technology - March/April 2025

Table of Contents for the Digital Edition of Magnetics Business & Technology - March/April 2025
